Dhargam Aljebouri: First Molecularly Characterized Para-Bombay Phenotype in the Arab World
Dhargam Aljebouri, Laboratory Director at Clinical Immunology, Allergy and Transfusion Medicine – Specialized Immunosciences Laboratory, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Transfusion, adding:
“Proud to share that our case report (First molecularly characterized Para-Bombay phenotype in Iraq: Clinical, serological and genetic insights with implications for transfusion safety), has now been published in Transfusion (The Journal of AABB).
This represents the first molecularly characterized Para-Bombay phenotype reported from Iraq and, to the best of my knowledge, the first published molecularly characterized Para-Bombay case from the Arab world.
This work highlights the value of integrating advanced immunohematology, secretor studies and molecular characterization of FUT1/FUT2 to improve recognition of H-deficient phenotypes and transfusion safety.
My sincere thanks to all co-authors for their valuable contributions and collaboration throughout this work, with special appreciation to the team of the Specialized Immunosciences Laboratory, Al-Moayed Medical Network for their dedicated technical support and laboratory efforts.
I dedicate this publication to the memory of my beloved sister, Zahraa.
A meaningful contribution to rare blood group science and transfusion medicine from Iraq.”
Title: First molecularly characterized Para-Bombay phenotype in Iraq: Clinical, serological and genetic insights with implications for transfusion safety
Authors: Dhargam Muhamed Aljebouri, Mohammed Aljadiri, Bassam Alshaikhli, Rawa Alattabi, Arwa Alkhamess, Sajjad Aldoori, Yousif Suleiman
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 19, 2026, 10:33Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval
-
Oct 19, 2026, 10:28Brig Tathagata Chatterjee: Acute Leukemias in AYAs at the Japanese Society of Hematology Conference
-
Oct 19, 2026, 10:27Heather M. Johnson: Join the Discussion on Optimizing the CTEPH Diagnostic Pathway
-
Oct 19, 2026, 10:18Flora Peyvandi: Unravelling the Complexity of VWF Through Genetics
-
Oct 19, 2026, 09:55High DOAC Adherence in Patients With Ischemic Stroke and AF – International Journal of Stroke
-
Oct 19, 2026, 08:20Cory Dugan: The IRONWOMAN Trial Individual Responses to IV Iron Therapy in Active Women
-
Oct 19, 2026, 07:36Johannes Kaesmacher: Cerebral No-Reflow After Thrombectomy Toward a Standardized Definition
-
Oct 19, 2026, 07:33Beth Psaila: Highlights from IACH Annual Meeting and MPN Horizons
-
Oct 19, 2026, 07:29Wolfgang Miesbach: Can Losartan Activate Brown Fat? – Nature Study Explores New Therapeutic Link